Kurs
+0,42%
Kalender
| Est. tid* | ||
| 2026-08-27 | 07:00 | Kvartalsrapport 2026-Q2 |
| 2026-05-21 | N/A | X-dag ordinarie utdelning ONCIN 0.00 NOK |
| 2026-05-20 | N/A | Årsstämma |
| 2026-02-26 | - | Bokslutskommuniké 2025 |
| 2026-01-19 | - | Split ONCIN 100:1 |
| 2026-01-08 | - | Extra Bolagsstämma 2026 |
| 2025-08-20 | - | Kvartalsrapport 2025-Q2 |
| 2025-06-26 | - | Årsstämma |
| 2025-05-21 | - | X-dag ordinarie utdelning ONCIN 0.00 NOK |
| 2025-02-26 | - | Bokslutskommuniké 2024 |
| 2024-11-13 | - | Kvartalsrapport 2024-Q3 |
| 2024-10-10 | - | Extra Bolagsstämma 2024 |
| 2024-08-21 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-30 | - | Split ONCIN 100:1 |
| 2024-05-29 | - | Kvartalsrapport 2024-Q1 |
| 2024-05-24 | - | X-dag ordinarie utdelning ONCIN 0.00 NOK |
| 2024-05-23 | - | Årsstämma |
| 2024-02-14 | - | Bokslutskommuniké 2023 |
| 2023-11-14 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-23 | - | Kvartalsrapport 2023-Q2 |
| 2023-06-22 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-22 | - | Årsstämma |
| 2023-04-21 | - | X-dag ordinarie utdelning ONCIN 0.00 NOK |
| 2023-02-16 | - | Bokslutskommuniké 2022 |
| 2022-11-15 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-23 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-24 | - | Kvartalsrapport 2022-Q1 |
| 2022-04-29 | - | X-dag ordinarie utdelning ONCIN 0.00 NOK |
| 2022-04-28 | - | Årsstämma |
| 2022-02-16 | - | Bokslutskommuniké 2021 |
| 2022-01-06 | - | Extra Bolagsstämma 2022 |
| 2021-11-16 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-17 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-19 | - | Kvartalsrapport 2021-Q1 |
| 2021-03-22 | - | X-dag ordinarie utdelning ONCIN 0.00 NOK |
| 2021-03-19 | - | Årsstämma |
| 2021-02-10 | - | Bokslutskommuniké 2020 |
| 2020-12-09 | - | Extra Bolagsstämma 2020 |
| 2020-11-17 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-18 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-19 | - | Kvartalsrapport 2020-Q1 |
| 2020-03-17 | - | X-dag ordinarie utdelning ONCIN 0.00 NOK |
| 2020-03-16 | - | Årsstämma |
| 2020-02-11 | - | Bokslutskommuniké 2019 |
| 2019-11-19 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-19 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-08 | - | Kvartalsrapport 2019-Q1 |
| 2019-03-14 | - | X-dag ordinarie utdelning ONCIN 0.00 NOK |
| 2019-03-13 | - | Årsstämma |
| 2019-02-19 | - | Bokslutskommuniké 2018 |
| 2018-11-13 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-21 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-15 | - | X-dag ordinarie utdelning ONCIN 0.00 NOK |
| 2018-05-15 | - | Kvartalsrapport 2018-Q1 |
| 2018-05-14 | - | Årsstämma |
| 2018-03-09 | - | Extra Bolagsstämma 2018 |
| 2018-02-13 | - | Bokslutskommuniké 2017 |
| 2017-11-17 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-18 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-23 | - | Kvartalsrapport 2017-Q1 |
| 2017-03-23 | - | X-dag ordinarie utdelning ONCIN 0.00 NOK |
| 2017-03-22 | - | Årsstämma |
| 2016-06-22 | - | X-dag ordinarie utdelning ONCIN 0.00 NOK |
| 2016-06-21 | - | Årsstämma |
| 2015-06-23 | - | X-dag ordinarie utdelning ONCIN 0.00 NOK |
| 2015-06-22 | - | Årsstämma |
Beskrivning
| Land | Norge |
|---|---|
| Lista | Oslo Bors |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Oslo, Norway, 5 May 2026: Reference is made to the stock exchange announcement made by Oncoinvent ASA (the "Company") on 8 January 2026 regarding the resolution by the extraordinary general meeting to decrease the share capital of the Company by NOK 222,800,997, from NOK 223,920,600 to NOK 1,119,603, through a reduction of the nominal value of the shares by NOK 49.75, from NOK 50 to NOK 0.25.
The resolution was published by the Norwegian Register of Business Enterprises on 22 January 2026 and followed by a six-week creditor notice period, which was completed without creditor objections.
The share capital decrease has today been registered as completed by the Norwegian Register of Business Enterprises. Following the share capital decrease, the share capital of the Company is NOK 1,119,603, divided into 4,478,412 shares, each with a nominal value of NOK 0.25.
For further information, please contact:
Oystein Soug, Chief Executive Officer
Email: IR@oncoinvent.com
This information is subject to the disclosure requirements pursuant to Euronext Oslo Rule Book II for companies listed on Oslo Børs and Section 5-12 of the Norwegian Securities Trading Act.